Jul. 16 at 11:18 AM
$AQST Yesterdays announcement will officially start the clock on negotiating their global partner(s).
With the results from the Anaphylm trials along with the announcement of starting the application process with these two Govt. agencies, will now give Barber the leverage needed to secure the global partner(s). The deal will be cut well before FDA approval. There will be an upfront payment followed by meeting certain milestone payments.
Think about it, if I were a big Pharma company, I would want to cut the deal early and secure product rights before the approval. Smart move would be to risk 50% now to secure rights before the FDA approval and then pay the balance upon meeting the milestone.
Total win for AQST, they get the cash, recieve future royalties and benefit from manufacturing the film to be sold to their future partner.
